{
    "organizations": [],
    "uuid": "08e4ae9ae86047ae30d71056dbd7f6416d636dc5",
    "author": "",
    "url": "https://www.reuters.com/article/brief-ovid-therapeutics-announces-ov101/brief-ovid-therapeutics-announces-ov101-granted-fast-track-designation-by-fda-for-fragile-x-syndrome-treatment-idUSASC09SEZ",
    "ord_in_thread": 0,
    "title": "BRIEF-Ovid Therapeutics Announces OV101 Granted Fast Track Designation By FDA For Fragile X Syndrome Treatment",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 25 PM / Updated 20 minutes ago BRIEF-Ovid Therapeutics Announces OV101 Granted Fast Track Designation By FDA For Fragile X Syndrome Treatment Reuters Staff 1 Min Read   Ovid Therapeutics Inc: * OVID THERAPEUTICS ANNOUNCES OV101 GRANTED FAST TRACK DESIGNATION BY U.S. FDA FOR TREATMENT OF FRAGILE X SYNDROME * OVID THERAPEUTICS INC - ‍INTENDS TO INITIATE A PHASE 2 CLINICAL TRIAL IN 2018​ * OVID - ‍TOPLINE DATA FROM PHASE 2 STARS CLINICAL TRIAL INVESTIGATING OV101 EXPECTED IN SECOND HALF OF 2018​ Source text for Eikon:  ",
    "published": "2018-03-15T14:23:00.000+02:00",
    "crawled": "2018-03-15T14:42:19.114+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "updated",
        "minute",
        "ago",
        "therapeutic",
        "announces",
        "ov101",
        "granted",
        "fast",
        "track",
        "designation",
        "fda",
        "fragile",
        "x",
        "syndrome",
        "treatment",
        "reuters",
        "staff",
        "min",
        "read",
        "ovid",
        "therapeutic",
        "inc",
        "ovid",
        "therapeutic",
        "announces",
        "ov101",
        "granted",
        "fast",
        "track",
        "designation",
        "fda",
        "treatment",
        "fragile",
        "x",
        "syndrome",
        "ovid",
        "therapeutic",
        "inc",
        "initiate",
        "phase",
        "clinical",
        "trial",
        "ovid",
        "data",
        "phase",
        "star",
        "clinical",
        "trial",
        "investigating",
        "ov101",
        "expected",
        "second",
        "half",
        "source",
        "text",
        "eikon"
    ]
}